A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
This study evaluates the safety and effectiveness of Aticaprant for people with depression.
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of Aticaprant for people with depression.
Who could participate?
Listed age limits: 18 years to 74 years.
- Listed locations
- Birmingham and 233 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 871
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, France, ...
- Age range
- From 18 Years to 74 Years
- Official registry ID
- NCT05518149
- Official title
Show the full official title
An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD)
Recruitment & locations
TerminatedBirmingham, United States · Tucson, United States · Anaheim, United States
175 more locations
- Culver City, United States
- Glendale, United States
- Lafayette, United States
- Long Beach, United States
- Oceanside, United States
- Orange, United States
- Rancho Cucamonga, United States
- San Diego, United States
- Santa Ana, United States
- Santee, United States
- Sherman Oaks, United States
- Temecula, United States
- Upland, United States
- West Covina, United States
- Colorado Springs, United States
- Farmington, United States
- Clearwater, United States
- Coral Springs, United States
- Fort Myers, United States
- Gainesville, United States
- Hialeah, United States
- Maitland, United States
- Miami, United States
- Miami Gardens, United States
- Miami Lakes, United States
- North Bay Village, United States
- Ocoee, United States
- Orange City, United States
- Orlando, United States
- Pompano Beach, United States
- Port Saint Lucie, United States
- Tampa, United States
- Berwyn, United States
- Chicago, United States
- Elgin, United States
- Skokie, United States
- Marrero, United States
- Monroe, United States
- Gaithersburg, United States
- Methuen, United States
- Ann Arbor, United States
- O'Fallon, United States
- Saint Charles, United States
- Buffalo, United States
- Mount Kisco, United States
- New York, United States
- Rochester, United States
- The Bronx, United States
- Charlotte, United States
- Cincinnati, United States
- Columbus, United States
- Dayton, United States
- Garfield Heights, United States
- Edmond, United States
- Oklahoma City, United States
- Allentown, United States
- Media, United States
- Moosic, United States
- Philadelphia, United States
- Austin, United States
- Bellaire, United States
- Dallas, United States
- Fort Worth, United States
- Houston, United States
- Katy, United States
- Clinton, United States
- Murray, United States
- Charlottesville, United States
- Bellevue, United States
- Buenos Aires, Argentina
- Ciudad Autonoma Buenos Aires, Argentina
- Córdoba, Argentina
- La Plata, Argentina
- Mendoza, Argentina
- Rosario, Argentina
- San Miguel de Tucumán, Argentina
- Santiago del Estero, Argentina
- Frankston, Australia
- Melbourne, Australia
- Alken, Belgium
- Brussels, Belgium
- Duffel, Belgium
- Sint-Niklaas, Belgium
- Curitiba, Brazil
- Fortaleza, Brazil
- Goiânia, Brazil
- Porto Alegre, Brazil
- Rio de Janeiro, Brazil
- São Bernardo, Brazil
- São José do Rio Preto, Brazil
- São Paulo, Brazil
- Cherven Bryag, Bulgaria
- Plovdiv, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Varna, Bulgaria
- Veliko Tarnovo, Bulgaria
- Sherbrooke, Canada
- Baoding, China
- Beijing, China
- Changsha, China
- Chengdu, China
- Guangzhou, China
- Huzhou, China
- Shanghai, China
- Shijiazhuang, China
- Suzhou, China
- Tianjin, China
- Wuhan, China
- Wuhu, China
- Xi'an, China
- Zhengzhou, China
- Brno, Czechia
- Klecany, Czechia
- Kutná Hora, Czechia
- Pilsen, Czechia
- Prague, Czechia
- Ústí nad Labem, Czechia
- Bohars, France
- Clermont-Ferrand, France
- Douai, France
- Nantes, France
- Paris, France
- Tours, France
- Budapest, Hungary
- Gyöngyös, Hungary
- Kalocsa, Hungary
- Pécs, Hungary
- Szekszárd, Hungary
- Bergamo, Italy
- Catanzaro, Italy
- Lecce, Italy
- Milan, Italy
- Siena, Italy
- Bełchatów, Poland
- Bialystok, Poland
- Bydgoszcz, Poland
- Gdansk, Poland
- Katowice, Poland
- Lodz, Poland
- Poznan, Poland
- Suchy Las, Poland
- Torun, Poland
- Braga, Portugal
- Lisbon, Portugal
- Banská Bystrica, Slovakia
- Bojnice, Slovakia
- Bratislava, Slovakia
- Košice, Slovakia
- Liptovský Mikuláš, Slovakia
- Rimavská Sobota, Slovakia
- Vranov nad Topľou, Slovakia
- Cape Town, South Africa
- Pretoria, South Africa
- Strand, South Africa
- Bucheon-si, South Korea
- Busan, South Korea
- Gyeonggi-do, South Korea
- Seoul, South Korea
- Barcelona, Spain
- Madrid, Spain
- Málaga, Spain
- Palma de Mallorca, Spain
- Ponferrada, Spain
- Sabadell, Spain
- Vigo, Spain
- Vitoria-Gasteiz, Spain
- Gothenburg, Sweden
- Lund, Sweden
- Stockholm, Sweden
- Taichung, Taiwan
- Taipei, Taiwan
- London, United Kingdom
- Southampton, United Kingdom
- Czechia
A listed location does not confirm current availability.
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of Aticaprant for people with depression.
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Does this study involve medication?
Yes. The study involves medication, including Aticaprant.
Who can participate?
Listed age limits: 18 years to 74 years.
Is this study still recruiting?
The registry lists this study as terminated.
